{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:59:14Z","timestamp":1791165554155,"version":"4.1.0"},"reference-count":34,"publisher":"Portland Press Ltd.","issue":"5","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Carboxypeptidase A4 (CPA4) is a member of the metallocarboxypeptidase family. Current studies have identified the roles of CPA4 in cancer biology and insulin sensitivity. However, the roles of CPA4 in other diseases are not known. In the present study, we investigated the roles of CPA4 in cardiac hypertrophy. The expression of CPA4 was significantly increased in the hypertrophic heart tissues of human patients and isoproterenol (ISO)-induced hypertrophic heart tissues of mice. We next knocked down Cpa4 with shRNA or overexpressed Cpa4 using adenovirus in neonatal rat cardiomyocytes and induced cardiomyocyte hypertrophy with ISO. We observed that Cpa4 overexpression promoted whereas Cpa4 knockdown reduced ISO-induced growth of cardiomyocyte size and overexpression of hypertrophy marker genes, such as myosin heavy chain \u03b2 (\u03b2-Mhc), atrial natriuretic peptide (Anp), and brain natriuretic peptide (Bnp). Our further mechanism study revealed that the mammalian target of rapamycin (mTOR) signaling was activated by Cpa4 in cardiomyocytes, which depended on the phosphoinositide 3-kinase (PI3K)-AKT signaling. Besides, we showed that the PI3K-AKT-mTOR signaling was critically involved in the roles of Cpa4 during cardiomyocyte hypertrophy. Collectively, these results demonstrated that CPA4 is a regulator of cardiac hypertrophy by activating the PI3K-AKT-mTOR signaling, and CPA4 may serve as a promising target for the treatment of hypertrophic cardiac diseases.<\/jats:p>","DOI":"10.1042\/bsr20200669","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T10:28:49Z","timestamp":1588156129000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Carboxypeptidase A4 promotes cardiomyocyte hypertrophy through activating PI3K-AKT-mTOR signaling"],"prefix":"10.1042","volume":"40","author":[{"given":"Weinian","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Cardiac Macrovascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shijiazhuang Translational Chinese Medicine Hospital, Shijiazhuang 050000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4093-1304","authenticated-orcid":false,"given":"Shuguang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiac Macrovascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiac Macrovascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiac Macrovascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Cardiac Macrovascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Cardiac Macrovascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"2021111620102557700_B1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","article-title":"Mechanisms of physiological and pathological cardiac hypertrophy","volume":"15","author":"Nakamura","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"2021111620102557700_B2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00280","article-title":"Cardiomyocyte senescence and cellular communications within myocardial microenvironment","author":"Tang","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2021111620102557700_B3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","article-title":"Physiological and pathological cardiac hypertrophy","volume":"97","author":"Shimizu","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2021111620102557700_B4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.phrs.2009.11.012","article-title":"Molecular targets and regulators of cardiac hypertrophy","volume":"61","author":"Rohini","year":"2010","journal-title":"Pharmacol. Res."},{"key":"2021111620102557700_B5","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1042\/CS20160685","article-title":"Mitochondrial sirtuins in cardiometabolic diseases","volume":"131","author":"Tang","year":"2017","journal-title":"Clin. Sci."},{"key":"2021111620102557700_B6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3389\/fendo.2018.00748","article-title":"Sirtuins and insulin resistance","volume":"9","author":"Zhou","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2021111620102557700_B7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jcp.21197","article-title":"Activation or inactivation of cardiac Akt\/mTOR signaling diverges physiological from pathological hypertrophy","volume":"214","author":"Kemi","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"2021111620102557700_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02795-4","article-title":"AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation","volume":"9","author":"G\u00e9linas","year":"2018","journal-title":"Nat. Commun."},{"key":"2021111620102557700_B9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.bbadis.2016.11.023","article-title":"FOXOs in the impaired heart: new therapeutic targets for cardiac diseases","volume":"1863","author":"Xin","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"2021111620102557700_B10","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.2174\/138161211796390976","article-title":"Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure","volume":"17","author":"Aoyagi","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"2021111620102557700_B11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cardiores.2004.02.003","article-title":"Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy","volume":"63","author":"Proud","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"2021111620102557700_B12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1042\/CS20200128","article-title":"Short-chain fatty acid, acylation and cardiovascular diseases","volume":"134","author":"Chen","year":"2020","journal-title":"Clin. Sci."},{"key":"2021111620102557700_B13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/CIRCRESAHA.117.311147","article-title":"New insights into the role of mTOR signaling in the cardiovascular system","volume":"122","author":"Sciarretta","year":"2018","journal-title":"Circ. Res."},{"key":"2021111620102557700_B14","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.bbamcr.2016.01.003","article-title":"mTOR, cardiomyocytes and inflammation in cardiac hypertrophy","volume":"1863","author":"Xu","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111620102557700_B15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fphys.2016.00104","article-title":"Rapamycin inhibits cardiac hypertrophy by promoting autophagy via the MEK\/ERK\/Beclin-1 pathway","volume":"7","author":"Gu","year":"2016","journal-title":"Front. Physiol."},{"key":"2021111620102557700_B16","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1161\/01.CIR.0000057979.36322.88","article-title":"Rapamycin attenuates load-induced cardiac hypertrophy in mice","volume":"107","author":"Shioi","year":"2003","journal-title":"Circulation"},{"key":"2021111620102557700_B17","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1073\/pnas.0500678102","article-title":"Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin","volume":"102","author":"Pallares","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111620102557700_B18","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/mc.23095","article-title":"Downregulation of CPA4 inhibits non small\u2013cell lung cancer growth by suppressing the AKT\/c-MYC pathway","volume":"58","author":"Fu","year":"2019","journal-title":"Mol. Carcinog."},{"key":"2021111620102557700_B19","first-page":"833","article-title":"Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer","volume":"54","author":"Handa","year":"2019","journal-title":"Int. J. Oncol."},{"key":"2021111620102557700_B20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/biom9030103","article-title":"Diagnostic and prognostic significance of carboxypeptidase A4 (CPA4) in breast cancer","volume":"9","author":"Bademler","year":"2019","journal-title":"Biomolecules"},{"key":"2021111620102557700_B21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1080\/08977194.2017.1285764","article-title":"Fibroblast growth factor-1 (FGF-1) promotes adipogenesis by downregulation of carboxypeptidase A4 (CPA4) - a negative regulator of adipogenesis implicated in the modulation of local and systemic insulin sensitivity","volume":"34","author":"He","year":"2016","journal-title":"Growth Factors"},{"key":"2021111620102557700_B22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3389\/fphys.2017.00356","article-title":"Protective role for LPA3 in cardiac hypertrophy induced by myocardial infarction but not by isoproterenol","volume":"8","author":"Cai","year":"2017","journal-title":"Front. Physiol."},{"key":"2021111620102557700_B23","doi-asserted-by":"publisher","first-page":"36576","DOI":"10.1038\/srep36576","article-title":"SIRT1 deacetylates the cardiac transcription factor Nkx2.5 and inhibits its transcriptional activity","volume":"6","author":"Tang","year":"2016","journal-title":"Sci. Rep."},{"key":"2021111620102557700_B24","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.117.028728","article-title":"SIRT2 acts as a cardioprotective deacetylase in pathological cardiac hypertrophy","volume":"136","author":"Tang","year":"2017","journal-title":"Circulation"},{"key":"2021111620102557700_B25","doi-asserted-by":"publisher","first-page":"e97999","DOI":"10.1371\/journal.pone.0097999","article-title":"The involvement of NFAT transcriptional activity suppression in SIRT1-mediated inhibition of COX-2 expression induced by PMA\/Ionomycin","volume":"9","author":"Jia","year":"2014","journal-title":"PLoS ONE"},{"key":"2021111620102557700_B26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s11427-014-4687-1","article-title":"Overexpression of a dominant-negative mutant of SIRT1 in mouse heart causes cardiomyocyte apoptosis and early-onset heart failure","volume":"57","author":"Mu","year":"2014","journal-title":"Sci. China Life Sci."},{"key":"2021111620102557700_B27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s11427-016-0131-4","article-title":"Human paraoxonase gene cluster overexpression alleviates angiotensin II-induced cardiac hypertrophy in mice","volume":"59","author":"Pei","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"2021111620102557700_B28","first-page":"2758","article-title":"Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice","volume":"119","author":"Sundaresan","year":"2009","journal-title":"J. Clin. Invest."},{"key":"2021111620102557700_B29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/iep.12315","article-title":"Carboxypeptidase A4 promotes proliferation and stem cell characteristics of hepatocellular carcinoma","volume":"100","author":"Zhang","year":"2019","journal-title":"Int. J. Exp. Pathol."},{"key":"2021111620102557700_B30","first-page":"5071","article-title":"Overexpression of carboxypeptidase A4 (CPA4) is associated with poor prognosis in patients with gastric cancer","volume":"8","author":"Sun","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"2021111620102557700_B31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ijbiomac.2019.07.028","article-title":"Carboxypeptidase A4 promotes cell growth via activating STAT3 and ERK signaling pathways and predicts a poor prognosis in colorectal cancer","volume":"138","author":"Pan","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"2021111620102557700_B32","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3892\/ijo.2011.1290","article-title":"NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations","volume":"40","author":"Park","year":"2012","journal-title":"Int. J. Oncol."},{"key":"2021111620102557700_B33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"2021111620102557700_B34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4236\/ajmb.2014.43015","article-title":"Endometrial carcinogenesis and molecular signaling pathways","volume":"4","author":"Ma","year":"2014","journal-title":"Am. J. Mol. Biol."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20200669\/878893\/bsr-2020-0669.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20200669\/878893\/bsr-2020-0669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:46:27Z","timestamp":1637095587000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/40\/5\/BSR20200669\/222873\/Carboxypeptidase-A4-promotes-cardiomyocyte"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,29]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20200669","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,5]]},"article-number":"BSR20200669"}}